Form 4: IMDX CEO vests RSUs; shares withheld for tax

Insight Molecular Diagnostics CEO Josh Riggs vested 47,170 RSUs on March 26, 2026, withheld 12,310 shares for taxes at $4.11, and now holds 38,365 common shares with 141,509 RSUs outstanding.

Summary

• On 03/26/2026, CEO and President Josh Riggs converted 47,170 RSUs into common stock under the 2018 Equity Incentive Plan (transaction code M).
• To cover tax withholding at $4.11 per share, 12,310 shares were withheld by the company (transaction code F); no open‑market sale occurred.
• Direct common stock holdings after the transactions total 38,365 shares; 141,509 RSUs remain outstanding.
• 25% of the RSU grant vested on March 26, 2026; the remaining 75% will vest in equal annual installments on the second-, third-, and fourth-year anniversaries of the grant, subject to continuous service.
• Riggs is a Director and Officer (CEO and President).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine, slightly positive insider update: equity vests as scheduled, no open-market selling, and incentives remain aligned; company fundamentals are unaffected.

Positives

• No open-market selling; shares were withheld solely to satisfy tax obligations.
• Multi-year vesting schedule aligns management incentives with shareholders over time.
• Post-transaction equity exposure remains significant (38,365 common shares plus 141,509 RSUs).

Negatives

• Issuance of 47,170 shares upon RSU vesting can modestly dilute existing shareholders.
• Share withholding reduced immediately tradable common shares by 12,310.

Future Outlook

Remaining 75% of the RSU grant is scheduled to vest in equal annual installments on the second-, third-, and fourth-year anniversaries of the grant, subject to continuous service; no operational or financial guidance is provided.

Management Comments

• Shares were withheld by the company solely to cover required tax withholding upon RSU vesting; no shares were sold.
• 25% of RSUs vested on March 26, 2026; the remaining 75% will vest in equal annual installments over the next three years, contingent on continuous service.

Industry Context

StockSavvy.ai notes that four-year RSU vesting with a 25% cliff followed by annual installments is standard across life sciences and diagnostics, serving as a retention tool and typically neutral for near-term valuation; routine tax-withholding at vest is common and generally has minimal market impact.

Comparison to Industry Standards

• Vesting structure aligns with peers such as Exact Sciences (EXAS), Guardant Health (GH), and Natera (NTRA), which commonly use four-year RSU vesting schedules with initial cliffs and subsequent periodic vesting.
• Share withholding at vest based on fair market value is a standard administrative practice across U.S.-listed biotech/diagnostics firms.
• Absence of open-market insider selling compares favorably to 10b5-1 sales programs, which can sometimes be interpreted as a negative short-term signal.

Stakeholder Impact

• Shareholders: Minor dilution from RSU issuance; no change to operating outlook is indicated.
• Employees/Management: Continued retention incentive via multi-year RSU vesting.
• Customers/Suppliers/Creditors: No direct impact disclosed.

Next Steps

• Remaining 75% of RSUs to vest in equal annual installments on the second-, third-, and fourth-year anniversaries of the grant, contingent on continued service.

Key Dates

Recommendation

This is a routine insider equity vesting event with no open-market sales and no change to fundamentals or guidance; a prudent investor would maintain a hold pending operational or financial updates.

Keywords

insider transaction, Form 4, restricted stock units, RSU vesting, tax withholding, equity incentive plan, Insight Molecular Diagnostics, IMDX, CEO, Josh Riggs, beneficial ownership, 2018 Equity Incentive Plan, molecular diagnostics